PL3980403T3 - Sole montelukastu i zawierające je kompozycje farmaceutyczne - Google Patents

Sole montelukastu i zawierające je kompozycje farmaceutyczne

Info

Publication number
PL3980403T3
PL3980403T3 PL20730277.9T PL20730277T PL3980403T3 PL 3980403 T3 PL3980403 T3 PL 3980403T3 PL 20730277 T PL20730277 T PL 20730277T PL 3980403 T3 PL3980403 T3 PL 3980403T3
Authority
PL
Poland
Prior art keywords
same
pharmaceutical compositions
compositions containing
montelukast salts
montelukast
Prior art date
Application number
PL20730277.9T
Other languages
English (en)
Inventor
Giuseppe Caliendo
Giuseppe Cirino
Ferdinando Fiorino
Francesco FRECENTESE
Marcelo Nicolas MUSCARA'
Elisa PERISSUTTI
Antonio Petti
Fiorentina ROVIEZZO
Vincenzo Santagada
Beatrice Severino
Original Assignee
Genetic S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic S.P.A. filed Critical Genetic S.P.A.
Publication of PL3980403T3 publication Critical patent/PL3980403T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20730277.9T 2019-06-07 2020-06-05 Sole montelukastu i zawierające je kompozycje farmaceutyczne PL3980403T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000008340A IT201900008340A1 (it) 2019-06-07 2019-06-07 Sali di montelukast e loro composizioni farmaceutiche
PCT/EP2020/065629 WO2020245358A1 (en) 2019-06-07 2020-06-05 Montelukast salts and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
PL3980403T3 true PL3980403T3 (pl) 2024-07-29

Family

ID=67957350

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20730277.9T PL3980403T3 (pl) 2019-06-07 2020-06-05 Sole montelukastu i zawierające je kompozycje farmaceutyczne

Country Status (6)

Country Link
US (1) US12453727B2 (pl)
EP (1) EP3980403B1 (pl)
ES (1) ES2977490T3 (pl)
IT (1) IT201900008340A1 (pl)
PL (1) PL3980403T3 (pl)
WO (1) WO2020245358A1 (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
US6880844B2 (en) 2002-12-05 2005-04-19 James C. Hayes Wind-assisted bicycle
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
EP1631550B1 (en) 2003-06-06 2012-01-11 Morepen Laboratories Ltd. An improved method for the preparation of montelukast acid sodium salt in amorphous form
KR20060117356A (ko) 2004-01-30 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 유리산 다형체
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
AU2008316284A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
GB0918431D0 (en) * 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.

Also Published As

Publication number Publication date
ES2977490T3 (es) 2024-08-26
EP3980403A1 (en) 2022-04-13
IT201900008340A1 (it) 2020-12-07
US20220218690A1 (en) 2022-07-14
US12453727B2 (en) 2025-10-28
EP3980403B1 (en) 2024-04-10
WO2020245358A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
IL263082B (en) New compounds as ototaxin inhibitors and pharmaceutical preparations containing them
EP3706741A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11201706877RA (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
GB201911517D0 (en) Pharmaceutical composition
GB201807053D0 (en) Pharmaceutical composition
GB201804548D0 (en) Pharmaceutical compositions
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
EP3960741A4 (en) QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND THEIR USES
SMT202400011T1 (it) Composizione farmaceutica
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
ZA202008034B (en) Ivosidenib forms and pharmaceutical compositions
GB201808571D0 (en) Pharmaceutical compositions
PT3778609T (pt) Derivados de penama ou sais dos mesmos, composições farmacêuticas e utilização das mesmas
IL285728A (en) Pharmaceutical composition
GB201808567D0 (en) Pharmaceutical compositions
IL276783A (en) The composition and pharmaceutical compound containing it
PL3949952T3 (pl) Kompozycja farmaceutyczna
SG11202103374TA (en) Pharmaceutical composition
PL3980403T3 (pl) Sole montelukastu i zawierające je kompozycje farmaceutyczne
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
PL4027974T3 (pl) Kompozycja farmaceutyczna zawierająca p-boronofenyloalaninę
GB201905509D0 (en) Pharmaceutical compositions and associated lits and uses
HUP1800273A2 (en) Stable pharmaceutical compositions and process for the preparation thereof